Fosmidomycin Targets Veterinary Staphylococcus Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of drug-resistant Staphylococcus infections poses a significant health threat, with existing antibiotics becoming less effective due to widespread resistance, and there is a lack of knowledge on how Staphylococcus species in veterinary medicine differ from those in human medicine, necessitating novel compounds for treatment.
Innovation Solution
Fosmidomycin, an inhibitor of the non-mevalonate pathway for isoprenoid biosynthesis, is administered to treat or prevent Staphylococcus infections in mammals and avian species, specifically targeting Staphylococcus species that use this pathway, such as S. schleiferi and S. pseudintermedius, which are common causes of skin and ear infections in animals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics are used to treat Staphylococcus infections, then treatment is effective against susceptible strains, but resistance develops leading to treatment failure
Solution Approach 1:
The patent changes the biochemical parameter of isoprenoid biosynthesis pathway from the mevalonate pathway (used by human-associated Staphylococcus) to the non-mevalonate pathway (used by veterinary-associated Staphylococcus). This parameter change allows fosmidomycin to selectively inhibit veterinary Staphylococcus species while leaving human-associated species unaffected, thereby maintaining treatment effectiveness while avoiding cross-resistance with conventional antibiotics.
2Reliability
If fosmidomycin is used to treat veterinary Staphylococcus infections, then selective efficacy against veterinary species is achieved, but potential toxicity to the animal host must be considered
Solution Approach 1:
The patent applies local quality by targeting a specific biochemical pathway (non-mevalonate pathway) that is locally present in veterinary Staphylococcus species but absent in the animal host. The animal host uses different metabolic pathways for isoprenoid biosynthesis, creating a local biochemical difference that allows selective inhibition of the pathogen while sparing the host, thus achieving high selective efficacy with low host toxicity.
3Ease of operation
If shared antibiotics are used in both human and veterinary medicine, then convenience of treatment is maintained, but cross-resistance and zoonotic transmission risks increase
Solution Approach 1:
The patent segments the Staphylococcus population into two distinct groups based on their isoprenoid biosynthesis pathways: human-associated species (mevalonate pathway) and veterinary-associated species (non-mevalonate pathway). By developing fosmidomycin that specifically targets the non-mevalonate pathway, the treatment is segmented to work exclusively on veterinary species, eliminating the risk of cross-resistance transmission to human medicine while maintaining ease of veterinary treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Fosmidomycin effectively treats multidrug-resistant Staphylococcus infections in animals without affecting human-associated Staphylococcus species, offering a targeted therapeutic approach by exploiting the divergent metabolic pathways between veterinary and human-associated Staphylococcus species, demonstrating low toxicity and high efficacy in clinical trials.
Implementation Method 1
Fosmidomycin, an inhibitor of the non-mevalonate pathway for isoprenoid biosynthesis
Data Source
AI summary
The invention includes a method of treating or preventing a Staphylococcus infection in a mammal or avian species in need thereof. The methods comprise administering to the mammal or avian species a therapeutically effective amount of fosmidomycin. In certain embodiments, the methods treat or prevent a drug-resistant Staphylococccus infection.